Cardiff Oncology, Inc.(CRDF)

Description: Cardiff Oncology, Inc., a clinical-stage, oncology therapeutic company, develops drugs to treat various types of cancer, including leukemia, lymphomas, and solid tumors. Its lead drug candidate is onvansertib, a Polo-like Kinase 1 selective adenosine triphosphate competitive inhibitor that is in Phase Ib/II clinical trial in acute myeloid leukemia (AML); has completed a Phase I clinical trial in advanced solid tumors; and Phase Ib/II clinical trial for metastatic Colorectal Cancer in combination with FOLFIRI and Avastin. The company's onvansertib is also in Phase II clinical trial in combination with Zytiga for metastatic castration-resistant prostate cancer; Phase I clinical trial with various chemotherapies and targeted therapeutics, such as Beleodaq (belinostat); Quizartinib (AC220), a development stage FLT3 inhibitor; and Velcade (bortezomib) used in leukemias, lymphomas, and solid tumor cancers. It primarily serves pharmaceutical companies. Cardiff Oncology, Inc. has a research collaboration with Nektar Therapeutics for the treatment of metastatic colorectal cancer. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2020. Cardiff Oncology, Inc. was founded in 1999 and is headquartered in San Diego, California.

---

Keywords: Medicine Pharmaceutical Cancer Clinical Medicine Drugs Solid Tumors Oncology Cancer Treatment Chemotherapy Prostate Cancer Lymphoma Phosphates Acute Myeloid Leukemia Leukemia Colorectal Cancer Antineoplastic Drugs Targeted Therapy Advanced Solid Tumors Metastatic Colorectal Cancer Adenosine Takeda Pharmaceutical Company Solid Tumor Cancers Metastatic Castration Resistant Prostate Cancer Resistant Prostate Cancer Cd135 Chemotherapies Bortezomib Nektar Therapeutics

---

Home Page: www.cardiffoncology.com

CRDF Technical Analysis

11055 Flintkote Avenue
San Diego, CA 92121
United States
Phone: 858 952 7570

---

Officers

Exchange: NASDAQ

Country: US

Currency: US Dollar ($)